A5077277131- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- vaccines and immunoinformatics approaches
- Advanced Breast Cancer Therapies
- Eosinophilic Disorders and Syndromes
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Biochemical and Molecular Research
- Estrogen and related hormone effects
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Colorectal and Anal Carcinomas
Genocea (United States)
2019-2023
NSABP Foundation
1996-2023
Daiichi Sankyo (United States)
2019
Exelixis (United States)
2011-2012
The Barbara Ann Karmanos Cancer Institute
2004-2011
Vanderbilt University
2011
Vanderbilt-Ingram Cancer Center
2011
Vall d'Hebron Hospital Universitari
2011
Columbia University Irving Medical Center
2011
Sanofi (United States)
2011
PURPOSE To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, relationship exists between tumor response to chemotherapy, such results the performance of more lumpectomies. PATIENTS AND METHODS Women (1,523) enrolled onto National Surgical Adjuvant Breast Bowel Project (NSABP) B-18 were randomly assigned or therapy. Clinical was graded as complete...
PURPOSE To determine whether preoperative doxorubicin and cyclophosphamide (AC) permits more lumpectomies to be performed decreases the incidence of positive nodes in women with primary breast cancer. PATIENTS AND METHODS Women (n = 1,523) were randomized National Surgical Adjuvant Breast Bowel Project (NSABP) B-18; 759 eligible patients received postoperative AC 747, AC. The clinical size axillary tumors was determined before each four cycles surgery. Tumor response therapy clinically...
The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth leukemic subclones with imatinib-resistant mutations. We evaluated dasatinib, that targets most mutations, patients chronic myelogenous leukemia (CML) or Ph-positive acute lymphoblastic (ALL).Patients various phases CML ALL who could not tolerate were resistant to enrolled phase 1 dose-escalation study. Dasatinib (15...
Background : In 1982, the National Surgical Adjuvant Breast and Bowel Project initiated a randomized, double-blinded, placebo-controlled trial (B-14) to determine effectiveness of adjuvant tamoxifen therapy in patients with primary operable breast cancer who had estrogen receptor-positive tumors no axillary lymph node involvement. The findings indicated that provided substantial benefit early stage disease. However, questions arose about how long observed would persist, duration necessary...
Background: The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be greater benefit than alone in treatment patients with axillary lymph node-negative, estrogen receptor- positive breast cancer. Methods: Eligible (n = 2306) were randomly assigned one three groups following surgery. A total 771 follow-up data received alone; 767 methotrexate, fluorouracil, (MFT); 768 cyclophosphamide, (CMFT)....
PURPOSE To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, relationship exists between tumor response to chemotherapy, such results the performance of more lumpectomies. PATIENTS AND METHODS Women (1,523) enrolled onto National Surgical Adjuvant Breast Bowel Project (NSABP) B-18 were randomly assigned or therapy. Clinical was graded as complete...
PURPOSE The National Surgical Adjuvant Breast and Bowel Project (NSABP) initiated a randomized trial (B-22) to determine if intensifying but maintaining the total dose of cyclophosphamide (Cytoxan, Bristol-Myers Squibb Oncology, Princeton, NJ) in doxorubicin (Adriamycin, Pharmacia, Kalamazoo, MI)-cyclophosphamide combination (AC), or increasing improves outcome women with primary breast cancer positive axillary nodes. PATIENTS AND METHODS Patients (N = 2,305) were receive either four courses...
We reviewed data from all adjuvant NSABP breast cancer trials that tested regimens containing both doxorubicin (A) and cyclophosphamide (C) to characterize the incidence of subsequent acute myeloid leukemia (AML) myelodysplastic syndrome (MDS).Six complete have investigated AC (B-15, B-16, B-18, B-22, B-23, B-25). Six distinct been are distinguished by differences in intensity cumulative dose presence or absence mandated prophylactic support with growth factor ciprofloxacin. In regimens, A...
In 1989, the National Surgical Adjuvant Breast and Bowel Project initiated B-22 trial to determine whether intensifying or increasing total dose of cyclophosphamide in a doxorubicin-cyclophosphamide combination would benefit women with primary breast cancer positive axillary nodes. B-25 was further yield more favorable results.Patients (n = 2,548) were randomly assigned three groups. The intensity doxorubicin similar all Group 1 received four courses, ie, double given standard therapy group;...
Neoantigens are critical targets of antitumor T-cell responses. The ATLAS bioassay was developed to identify neoantigens empirically by expressing each unique patient-specific tumor mutation individually in Escherichia coli, pulsing autologous dendritic cells an ordered array, and testing the patient's T for recognition overnight assay. Profiling from patients with lung cancer revealed both stimulatory inhibitory responses individual neoantigens. In murine B16F10 melanoma model, therapeutic...
Abstract Purpose: The oral fluoropyrimidine S-1, which consists of a mixture 5-fluorouracil (5-FU) prodrug (tegafur), dihydropyrimidine dehydrogenase inhibitor [5-chloro-2,4-dihydroxypyrimidine (CDHP)], and an orotate phosphoribosyltransferase [potassium oxonate (oxonic acid)], was developed to increase the feasibility therapeutic index 5-FU administered orally. principal objective this study assess administering S-1 on once-daily-for-28-day schedule every 5 weeks, determine maximum...
6519 Background: Resistance to imatinib in CML patients is often associated with Bcr-Abl point mutations which interfere binding. BMS-354825 a novel, orally available, dual SRC/ABL kinase inhibitor more than 300-fold greater potency and has preclinical activity against 14 of 15 resistant mutants (Shah et al, Science, 305:399, 2004). Methods: CA180002 phase I, dose-escalation study hematologic resistance or intolerance imatinib. Intrapatient dose escalation permitted. Patient samples are...
6520 Background: Response to imatinib in accelerated phase (AP) and blast (BP) CML is inferior chronic (CP). Relapse frequent associated with Bcr-Abl point mutations which interfere binding. BMS-354825 an orally available, dual SRC/ABL kinase inhibitor 300-fold greater potency than imatinib. has preclinical activity against 14 of 15 resistant mutants (Shah et al, Science, 2004). Methods: CA180002 a I, dose-escalation study patients resistance or intolerance The was initially restricted CP...
3510 Background: XL765 is a selective dual oral inhibitor of Class I PI3K isoforms and mTOR. potent in vivo pathway signaling leading to tumor growth inhibition or shrinkage dose dependent manner multiple human xenograft models exhibiting dysregulated signaling. Methods: Pts with advanced solid malignancies are enrolled successive cohorts 3 receive orally bid for cycles 28 days. Cycle 1 safety data determine dose-limiting toxicities (DLT). Pharmacodynamic samples collected. Tumor response...
3087 Background: Tumor-targeted drug delivery technologies are urgently needed to overcome conventional chemotherapy’s lack of tumor selectivity. Alphalex conjugates, which contain a pH-low insertion peptide (pHLIP), linker and payload, designed this Unlike antibody alphalex PDCs target tumors in an antigen-agnostic manner. At pH ≥7.0, the is unstructured. In low-pH microenvironment forms alpha helix inserts directionally into cell membrane delivering payload intracellularly where cleaved...
3107 Background: Tumor-specific neoantigens provide personalized targets for immunotherapy. Vaccines against epitopes predicted by in silico approaches very rarely induce CD4 + and CD8 ex vivo T cell responses regardless of formulation. ATLAS selects vaccine inclusion using screening all patient-specific mutations to identify pre-existing or exclude Inhibigens, which are inhibitory peptides that suppress immunity accelerate tumor progression. The Inhibigen burden correlates with patient...
Abstract BACKGROUND: Most HER2+ MBC patients (pts) treated with a combination of T+P progress within 1 year. Activation downstream pathways through either deficiency in PTEN or mutations the PI3K pathway has been implicated development resistance to T. S08 is potent, orally bioavailable, pan-PI3K inhibitor that inhibits phosphorylation multiple components PI3K/PTEN signaling and demonstrated activity as single agent other anticancer agents (Edelman G, et al., ASCO 2010; Traynor AM, al....